Selectivity Determination via Phenotypic Cell Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the selectivity of test compounds in complex cellular mixtures are limited by the need for absolute cell number measurement, which is prone to errors and requires multiple concentration points, failing to account for the interplay between different cell populations.
Innovation Solution
A method that determines selectivity by measuring the fraction of cells with a desired phenotype relative to the total cell population, allowing for robustness against variations in cell numbers and cell loss, and eliminating the need for absolute cell quantification and multiple concentration points.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If absolute cell number measurement is used to determine selectivity, then measurement precision is improved, but device complexity and sample requirements increase
Solution Approach 1:
The patent extracts the essential information needed for selectivity measurement by focusing on phenotypic changes rather than absolute cell counts. The method determines selectivity through the ratio of cells with specific phenotypes (e.g., apoptosis, proliferation) in treated versus control samples, eliminating the need for complex absolute quantification systems while maintaining measurement accuracy.
Solution Approach 2:
The patent changes the measurement parameter from absolute cell number to phenotypic state ratio. By measuring the proportion of cells exhibiting specific phenotypes (such as membrane blebbing for apoptosis or nuclear morphology changes) rather than total cell count, the method achieves accurate selectivity assessment without requiring complex quantification infrastructure.
2Measurement precision
If multiple concentration points are used to determine selectivity, then measurement precision is improved, but loss of time and sample quantity increase
Solution Approach 1:
The patent applies partial action by using a single representative concentration point instead of multiple concentrations to determine selectivity. The method assumes that the phenotypic ratio at one concentration adequately represents the compound's selective effect, thereby reducing assay time and sample consumption while maintaining sufficient measurement precision for drug development decisions.
Solution Approach 2:
The patent segments the measurement into two distinct components: the phenotypic state of target cells and the phenotypic state of off-target cells. By measuring these separately and calculating their ratio, the method achieves accurate selectivity assessment without requiring multiple concentration points, thus reducing time and sample requirements.
3Measurement precision
If cell populations are measured in isolation, then measurement precision is improved, but loss of information about cell-cell interactions occurs
Solution Approach 1:
The patent merges the measurement of target and off-target cell populations within the same mixed cell sample. By maintaining the natural cell population structure (e.g., tumor cells with stromal cells, immune cells, or normal cells) and measuring phenotypic ratios across the entire mixture, the method preserves information about cell-cell interactions and microenvironmental effects while still achieving precise selectivity measurement.
Solution Approach 2:
The patent creates a universal measurement approach that works across different cell types and disease models by focusing on phenotypic state ratios rather than absolute counts. This universal method can be applied to various mixed cell populations (cancer cells with normal cells, immune cell subsets, etc.) without requiring separate analysis for each cell type, thereby preserving interpopulation interaction information.
Data Source
AI summary
The invention relates to methods for determining the selectivity of a test compound and related methods such as methods for determining whether a subject suffering from cancer will respond or is responsive to treatment with a test compound or compositions comprising more than one test compound.